(Q38164866)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262158%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Predictors of Parkinson's disease dementia: towards targeted therapies for a heterogeneous disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262158%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

Parkinson's disease dementia

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262158%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Roger A. Barker

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262158%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Sarah F Moore

series ordinal

1

1 reference

30 August 2017

publication date

1 January 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262158%20AND%20SRC:MED&resulttype=core&format=json

Parkinsonism and Related Disorders

1 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262158%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

20 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262158%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

S104-7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262158%20AND%20SRC:MED&resulttype=core&format=json

The association of incident dementia with mortality in PD.

1 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

Clinical diagnostic criteria for dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

Mild cognitive impairment in Parkinson's disease: millstone or milestone?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

The effect of age of onset of PD on risk of dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

Changes in motor subtype and risk for incident dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

Rivastigmine for dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

Memory and executive function impairment predict dementia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

Rapid eye movement sleep behavior disorder and risk of dementia in Parkinson's disease: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

Clinical significance of REM sleep behavior disorder in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson's disease with dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

[11C]PIB binding in Parkinson's disease dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

Distinct α-synuclein strains differentially promote tau inclusions in neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

The link between the GBA gene and parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2813%2970026-9

7 January 2021

10.1016/S1353-8020(13)70026-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262158%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference